WO2000040752A3 - Cancer associated genes and their products - Google Patents

Cancer associated genes and their products Download PDF

Info

Publication number
WO2000040752A3
WO2000040752A3 PCT/GB1999/004359 GB9904359W WO0040752A3 WO 2000040752 A3 WO2000040752 A3 WO 2000040752A3 GB 9904359 W GB9904359 W GB 9904359W WO 0040752 A3 WO0040752 A3 WO 0040752A3
Authority
WO
WIPO (PCT)
Prior art keywords
products
associated genes
cancer associated
cancer
genes
Prior art date
Application number
PCT/GB1999/004359
Other languages
French (fr)
Other versions
WO2000040752A2 (en
Inventor
Robert Charles Rees
Geng Li
Original Assignee
Univ Nottingham Trent
Robert Charles Rees
Geng Li
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Nottingham Trent, Robert Charles Rees, Geng Li filed Critical Univ Nottingham Trent
Publication of WO2000040752A2 publication Critical patent/WO2000040752A2/en
Publication of WO2000040752A3 publication Critical patent/WO2000040752A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Abstract

The application discloses cancer-associated genes and their products, especially those identifiable by SEREX. The genes and products are used to identify, track and treat cancer such as prostate cancer.
PCT/GB1999/004359 1998-12-30 1999-12-22 Cancer associated genes and their products WO2000040752A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9828840.0A GB9828840D0 (en) 1998-12-30 1998-12-30 Prostate cancer associated genes and their products
GB9828840.0 1998-12-30

Publications (2)

Publication Number Publication Date
WO2000040752A2 WO2000040752A2 (en) 2000-07-13
WO2000040752A3 true WO2000040752A3 (en) 2000-11-23

Family

ID=10845169

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/004359 WO2000040752A2 (en) 1998-12-30 1999-12-22 Cancer associated genes and their products

Country Status (2)

Country Link
GB (1) GB9828840D0 (en)
WO (1) WO2000040752A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6573095B1 (en) 1998-04-29 2003-06-03 Genesis Research & Development Corporation Limited Polynucleotides isolated from skin cells
AU2001245693A1 (en) * 2000-03-16 2001-10-03 Northwest Biotherapeutics, Inc. Human paris-1 antigen and nucleic acids: diagnostic and therapeutic uses
AU2001260847A1 (en) * 2000-05-24 2001-12-03 Genesis Research And Development Corporation Limited Compositions isolated from skin cells and methods for their use
CA2433740A1 (en) * 2001-01-09 2002-07-18 Keio University Human glioma antigen and process for preparing the same
US7414032B2 (en) 2001-06-25 2008-08-19 Immunofrontier, Inc. Vaccine comprising a polynucleotide encoding an antigen recognized by a CD4+ helper T-cell and a polynucleotide encoding a tumor specific or associated antigen recognized by a CD8+ CTL
GB0218468D0 (en) * 2002-08-08 2002-09-18 Univ Nottingham Trent Gastric and Colon Cancer-associated antigens
EP1862803A1 (en) 2006-06-02 2007-12-05 Atlas Antibodies AB Use of protein SATB2 as a marker for colorectal cancer
EP2172477A1 (en) * 2008-10-06 2010-04-07 Atlas Antibodies AB Epitopes derived from SATB2 and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009820A1 (en) * 1992-11-05 1994-05-11 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen
WO1995004548A1 (en) * 1993-08-11 1995-02-16 Jenner Technologies Prostatic cancer vaccine
WO1997033909A2 (en) * 1996-03-15 1997-09-18 Corixa Corporation Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer
WO1998041648A2 (en) * 1997-03-20 1998-09-24 Variagenics, Inc. Target genes for allele-specific drugs
WO1999004265A2 (en) * 1997-07-17 1999-01-28 Ludwig Institute For Cancer Research Cancer associated nucleic acids and polypeptides

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009820A1 (en) * 1992-11-05 1994-05-11 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen
WO1995004548A1 (en) * 1993-08-11 1995-02-16 Jenner Technologies Prostatic cancer vaccine
WO1997033909A2 (en) * 1996-03-15 1997-09-18 Corixa Corporation Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer
WO1998041648A2 (en) * 1997-03-20 1998-09-24 Variagenics, Inc. Target genes for allele-specific drugs
WO1999004265A2 (en) * 1997-07-17 1999-01-28 Ludwig Institute For Cancer Research Cancer associated nucleic acids and polypeptides

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ERLICH ET AL.: "MOLECULAR CHARACTERIZATION OF TRANS-GOLGI p230", J.BIOL.CHEM., vol. 271, no. 14, 1996, pages 8328 - 8337, XP002136608 *
FRITZLER ET AL.: "MOLECULAR CHARACTERIZATION OF GOLGIN-245, A NOVEL GOLGI COMPLEX PROTEIN CONTAINING A GRANIN SIGNATURE", J.BIOL.CHEM., vol. 270, no. 52, 1995, pages 31262 - 31268, XP002136607 *
SAHIN U ET AL: "Human neoplasms elicit multiple specific immune responses in the autologous host", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,US,NATIONAL ACADEMY OF SCIENCE. WASHINGTON, vol. 92, no. 25, 5 December 1995 (1995-12-05), pages 11810 - 11813, XP002129692, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
GB9828840D0 (en) 1999-02-17
WO2000040752A2 (en) 2000-07-13

Similar Documents

Publication Publication Date Title
GB2368796A (en) Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
WO2000028090A3 (en) Diagnostic assay for cancer
MXPA03003151A (en) Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer.
WO1998016507A3 (en) New heterocyclylmethyl-substituted pyrazol derivates and their use for treating cardiovascular diseases
IL147017A0 (en) TREATING PROSTATE CANCER WITH ANTI-ErbB2 ANTIBODIES
AU3499395A (en) Ionene polymers containing biologically-active anions
WO2004034990A3 (en) Methods and compositions for use in treating cancer
AU5047800A (en) Breast, gastric and prostate cancer associated antigens and uses therefor
PL330496A1 (en) Methods of and compositions for treating and preventing tumours, disorders associated with tumours as well as cachexy
AU4903101A (en) Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
WO2004058153A9 (en) Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476.
CA2301032A1 (en) A method of preventing or treating estrogen-dependent diseases and disorders
WO2002030465A3 (en) Compositions that inhibit proliferation of cancer cells
ZA200202822B (en) Oncolytic combinations for the treatment of cancer.
AU2158601A (en) Antiviral agent for use in treatment of cancer
HK1040983A1 (en) Quinones for treatment of diseases.
AU4823599A (en) Prostate cancer-associated genes
WO2000040752A3 (en) Cancer associated genes and their products
WO2001053524A3 (en) Cancer associated genes and their products
WO2000053231A3 (en) Fatty acid-anticancer conjugates and uses thereof
AP2004003070A0 (en) The method of treating cancer.
AU3896899A (en) Compositions for the treatment of tumors, and uses thereof
ZA200002546B (en) Sorbate-preserved compositions, method for the manufacture thereof and their use.
AU1991901A (en) Pharmaceutical composition for treating and preventing human tumors, which express the tumor antigen mucin and/or the carcinoembryonic antigen (cea), and the use thereof
ZA200203166B (en) Treatment of cancer.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP NO US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP NO US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

122 Ep: pct application non-entry in european phase